OPA1 and Parkinson disease: Although OPA1 levels were increased in healthy subject controls, mutant LRRK2 G2019S (p < 0.001), R1441C (p < 0.001) and less-sensitive sporadic lines (p < 0.001), following LRRK2 kinase inhibition, levels were not restored in more sensitive sporadic PD-derived fibroblast lines (Supp.